Back
Amgen Inc. (AMGN)
BiotechnologyAMGN · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$442.23
−0.36%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$14.23
ROE
101.3%
Gross margin
71.4%
Debt/Equity
6.24x
Revenue growth
5.8%
Amgen Inc. — company intelligence
Earnings surprises
Q2 2026$6.29 vs $5.73 est+9.8%
Q1 2026$5.15 vs $4.85 est+6.1%
Q4 2025$5.29 vs $4.83 est+9.6%
Q3 2025$5.64 vs $5.11 est+10.3%
Analyst consensus · 43 analysts
21 Buy19 Hold3 Sell
Updated Aug 8, 2026
Insider activity · 90 days
4 buys1 sellnet -1,018 shares
Khosla Rachnaother 1,252 · Aug 13, 2026
Khosla RachnaSell 2,000 · Aug 11, 2026
HOLLEY CHARLES MBuy 103 · Aug 7, 2026
Recent SEC filings
4 — Insider transaction reportAug 13, 2026
4 — Insider transaction reportAug 12, 2026
4 — Insider transaction reportAug 10, 2026
Latest news
Why the Dow Is Beating the Nasdaq Again — Yahoo · 4d ago
Making Drugs With AI: Biopharma Giants Gear Up For New Arena — Yahoo · 4d ago
Amgen (AMGN) Gets A Fresh Target, Is It Fully Priced? — Yahoo · 4d ago
Global DLL3 Targeted Therapies Market 2026-2030: Profiles Amgen, Zai Lab, Boehringer Ingelheim and Phanes Therapeutics — Yahoo · 5d ago
Piper Sandler Maintains Overweight on Amgen, Raises Price Target to $457 — Benzinga · 5d ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.